Polyalkylimide (Bio-Alcamid)

Polyalkylimide, marketed as Bio-Alcamid  by its Italian manufacturer Polymekon, is injected into the face and forms a soft gel replacement for lost fat. Its manufacturers say that it should not degrade or move. Clinical results so far have found polyalkylimide gel to be safe and effective for treating facial lipoatrophy. In a trial design similar to the UK polylactic acid trial, a Canadian study compared immediate to deferred treatment to allow for a control group comparison, while still providing treatment to all participants. This randomised, prospective clinical trial found significant improvement in both physician- and patient-rated degree of facial lipoatrophy, quality of life, and depression.1

References

  1. Loutfy M et al. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS 21: 1147-1155, 2007
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.